Cagrilintide + Tirzepatide Quick Start The cagrilintide + tirzepatide stack pairs two once-weekly weight-loss peptides
Research Dose Ranges Preclinical animal studies: 110 mcg/kg (nanogram to microgram range) once or twice daily Extrapolated human equivalent range commonly discussed in clinical literature: 200500 mcg/day Human pilot IV data: doses up to 20 mg were tolerated without adverse effects in two healthy adults (Lee & Burgess, 2025) though this is far above typical outpatient dosing Protocol: Musculoskeletal / Connective Tissue Healing For tendon, ligament, or muscle injury recovery, the standard approach in clinical functional medicine practice involves: SubQ injection at 200500 mcg once daily , injected near (not into) the injury site Cycle length: typically 48 weeks , with reassessment Often combined with TB-500 (thymosin beta-4) for synergistic tissue remodeling the BPC+TB stack Best results seen alongside physical therapy, not as a substitute for it Protocol: Gut and GI Mucosal Healing For IBD, gut permeability, NSAID damage, or H
Growth HormoneRelated Peptides Examples include: CJC-1295 (a GHRH analogue) Ipamorelin (a growth hormone secretagogue) GHRP-2 (a growth hormone secretagogue) These peptides stimulate the bodys growth hormone signaling pathways, which can influence connective tissue metabolism
Most protocols are every other day or 2x/week during the "on" phase, not daily
Buprenorphine Dextromoramide Diamorphine (heroin) Fentanyl and its derivatives Hydromorphone Methadone Morphine Nicomorphine Oxycodone Oxymorphone Pentazocine Pethidine Tramadol S8 CANNABINOIDS In competition All prohibited substances in this class are Specified Substances
Seven of the 22 peptides associated with the frail vs control diagnostic contrast and cognitive decline were cytoskeleton-related, including proteoforms of MAP2, VIM, TUBB, DBN1, TUBA8, PALM and NEFM (Fig
